537 related articles for article (PubMed ID: 34963563)
1. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Ye W; Shi L; Qian L; Sun Y; Sun X
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
[TBL] [Abstract][Full Text] [Related]
5. Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study.
Zhou J; Huang J; Zhou Z; Deng X; Wu Q; Wang Z
Int J Colorectal Dis; 2024 Mar; 39(1):38. PubMed ID: 38492080
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of neoadjuvant CapeOX/mFOLFOX6 without radiation for patients with baseline resectable mid-low locally advanced rectal cancer.
Zhao X; He ZR; Han PY; Cai ZH; Fu ZW; Zhang LY; Sun J; Ma JJ; Dong F; Zang L; Zheng MH
J Dig Dis; 2022 Dec; 23(12):695-704. PubMed ID: 36661868
[TBL] [Abstract][Full Text] [Related]
8. Intensified Total Neoadjuvant Therapy
DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation.
Wu J; Huang M; Wu Y; Hong Y; Cai L; He R; Luo Y; Wang P; Huang M; Lin J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8897-8912. PubMed ID: 37154929
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial.
Yang W; Qian C; Luo J; Chen C; Feng Y; Dai N; Li X; Xiao H; Yang Y; Li M; Li C; Wang D
Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):233-242. PubMed ID: 38342657
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
12. Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies.
Zhang J; Xie X; Wu Z; Hu H; Cai Y; Li J; Ling J; Ding M; Li W; Deng Y
Clin Colorectal Cancer; 2021 Dec; 20(4):e240-e248. PubMed ID: 34334298
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.
Li A; Huang T; Zheng R; Chi P; Li Z; Wang X; Xu B
BMC Cancer; 2022 Jul; 22(1):789. PubMed ID: 35850711
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
16. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
17. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
[TBL] [Abstract][Full Text] [Related]
18. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
[TBL] [Abstract][Full Text] [Related]
19. Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis.
Yamaguchi T; Akiyoshi T; Fukunaga Y; Sakamoto T; Mukai T; Hiyoshi Y; Nagasaki T; Taguchi S; Chino A; Shinozaki E; Yamaguchi K; Konishi T
Ann Surg Oncol; 2023 Aug; 30(8):4716-4724. PubMed ID: 37032405
[TBL] [Abstract][Full Text] [Related]
20. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
